About Senses Pharmaceuticals Private Limited
Data last updated: 06 January 2026
Senses Pharmaceuticals Private Limited is a private limited company based in Bangalore North, Karnataka, India, a subsidiary of Til Healthcare Private Limited. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 26 November 2008, the company has been in operation for over 18 years.
Registered with ROC Bangalore under CIN U24232KA2008PTC048422.
Capital: an authorised share capital of ₹5.05 Cr and a paid-up capital of ₹11.12 Lakh. Formerly known as Senses Pharmaceuticals Limited. It is led by directors including Velayudham Suresh and Rangarajan Vijayaragavan.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Bangalore North, Karnataka.
As per the financials filed for FY 2025, the company reported a revenue of ₹26.08 Cr, a growth of 0% compared to the previous year.
The company has a workforce of approximately 154 employees as per the latest available data. It operates as a subsidiary of Til Healthcare Private Limited.
As per MCA filings, the company has open charges of ₹8.5 Cr and satisfied charges of ₹2.25 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sensespharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressNo.124 5Th Main Road Yeshwanthpur, Suburb 2Nd Stage, Bangalore North, Karnataka, India – 560022
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Senses Pharmaceuticals Private Limited
Senses Pharmaceuticals Private Limited has one previous CIN (Corporate Identification Number): U24232KA2008PLC048422. The current CIN is U24232KA2008PTC048422, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232KA2008PTC048422 | Current |
| U24232KA2008PLC048422 | Previous |
Business Activity of Senses Pharmaceuticals Private Limited
Senses Pharmaceuticals Private Limited is engaged in principal business activities including trade and manufacturing, with detailed activities including wholesale trading, chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Senses Pharmaceuticals Private Limited
Senses Pharmaceuticals Private Limited is audited by M.K.DANDEKER & CO for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| M.K.DANDEKER & CO | blur-value | blur-value | blur-value |
Board of Directors of Senses Pharmaceuticals Private Limited
Senses Pharmaceuticals Private Limited is currently managed by 4 directors, with 11 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Velayudham Suresh
Also directs:
Senses Pharmaceuticals Private Limited, Quest Teleradiology Solutions Private Limited, Akam Innovations Private Limited and 1 more
|
Director | 04 Apr 2018 | 8 Years 3 Months | Current |
|
Rangarajan Vijayaragavan
Also directs:
Injectalis Lifesciences Private Limited, Til Healthcare Private Limited, Senses Pharmaceuticals Private Limited and 4 more
|
Director | 10 Jun 2022 | 4 Years 0 Months | Current |
| Sundaresan Rajagopalan | Director | 04 Apr 2018 | 8 Years 3 Months | Current |
| Kapil Jhaver | Director | 09 Jun 2020 | 6 Years 1 Months | Current |
Financials of Senses Pharmaceuticals Private Limited FY 2025 filings available
Senses Pharmaceuticals Private Limited reported revenue of ₹26.08 Cr (up 0% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Senses Pharmaceuticals Private Limited
As of FY 2023, Senses Pharmaceuticals Private Limited's shareholding pattern shows 40.13% by promoters, 59.87% by public shareholders. Public shareholders hold the majority stake, reflecting broad public ownership.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Senses Pharmaceuticals Private Limited
Senses Pharmaceuticals Private Limited has 1 associated company. This group structure data is as of FY 2023. The corporate group structure reflects Senses Pharmaceuticals Private Limited's business expansion strategy and organizational complexity.
Charges & Borrowings of Senses Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 May 2015 | Hdfc Bank Limited | ₹8.5 Cr | Open |
| 12 Apr 2016 | Others | ₹25 Lakh | Satisfied |
| 10 Sep 2009 | State Bank of India | ₹2 Cr | Satisfied |
Total charge records: 3 View all charges
Employees and EPFO Compliance at Senses Pharmaceuticals Private Limited
Senses Pharmaceuticals Private Limited has a workforce of 154 employees as of Apr 01, 2024.
Employee Count & EPFO Data of Senses Pharmaceuticals Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Senses Pharmaceuticals Private Limited
GSTIN & GST Filing Data of Senses Pharmaceuticals Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Senses Pharmaceuticals Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Senses Pharmaceuticals Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Senses Pharmaceuticals Private Limited
MSME Payment Delays by Senses Pharmaceuticals Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Senses Pharmaceuticals Private Limited
Subsidiaries & Group Companies of Senses Pharmaceuticals Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Senses Pharmaceuticals Private Limited with ownership details.
MCA Filings & Documents of Senses Pharmaceuticals Private Limited
MCA Filings & Documents of Senses Pharmaceuticals Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Senses Pharmaceuticals Private Limited
Frequently Asked Questions about Senses Pharmaceuticals Private Limited
Senses Pharmaceuticals Private Limited is an active private limited company in the pharma sector based in Bangalore North, Karnataka, India. It was incorporated on 26 November 2008 (18+ years old) and is registered under CIN U24232KA2008PTC048422. The company has 154 employees.
Senses Pharmaceuticals Private Limited reported revenue of ₹26.08 Cr for FY 2025 (up 0.00% YoY).
The current directors of Senses Pharmaceuticals Private Limited are:
The primary industry of Senses Pharmaceuticals Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Senses Pharmaceuticals Private Limited can be reached at the registered office: No.124 5Th Main Road Yeshwanthpur, Suburb 2Nd Stage, Bangalore North, Karnataka, India – 560022, or through the website sensespharma.com.
The authorised capital is ₹5.05 Cr, and the paid-up capital is ₹11.12 Lakh.